AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03857529 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation and electrical stimulator
Description: Contralaterally Controlled Functional Electrical Stimulation: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator will be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).~Transcranial direct current stimulation (tDCS): TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration.
Study NCT02762942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses
Study NCT02762942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses
Study NCT02762942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: Insertion of a Foley catheter (16French) through the internal os for a maximum of 12 hours
Study NCT01346696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)
Study NCT04180020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ID/LAB
Description: ID/LAB is the new model in which OUD is managed by Infectious Disease (ID) specialists and/or Hospitalists concurrent with management of the infectious diseases, using long-acting injectable buprenorphine (LAB).
Study NCT04180020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU is designed to systematize what is the current practice at the participating hospitals and in most U.S. hospitals while offering a minimum standard of care. TAU will constitute recommendation for MOUD initiation and consultation for addiction medicine when available; in practice, it is typically detoxification from opioids and referral to community-based addiction treatment after hospital discharge.
Study NCT04031846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)
Study NCT04031846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)
Study NCT04031846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)
Study NCT04031846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)
Study NCT04031846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevenar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,
Study NCT04031846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13™
Description: 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.
Study NCT02510664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Strengths Study
Description: The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments.
Study NCT04597606 — intervention group
Intervention type: OTHER
Intervention: Exercise with spontaneous ventilation.
Description: Patients will perform 10 minutes, constant load, exercise in a cycloergometer. To set the load, a baseline incremental effort test will be performed previously (VISIT 1).~Then, in a separate day (VISIT 2), the subject will perform 10 minutes cycling at the 75% load of that determined as maximum in VISIT 1, at a constant rate of 30 to 35 pedal revolutions per minute, in spontaneous breathing, with low flow oxygen through conventional nasal cannula adjusted to achieve SpO2 between 92to 94%
Study NCT02393794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Monoclonal antibody, checkpoint inhibitor
Study NCT04597606 — intervention group
Intervention type: DEVICE
Intervention: Exercise with NIV
Description: VISIT 2 Non invasive mask ventilation: parameters will be titrated during a free cycling period at the end of the spontaneous breathing exercise. Then, in a separate day (VISIT 3), with the same constant load, cycling cadence and under NIV, the patient will perform 10 min of cycling.
Study NCT04597606 — intervention group
Intervention type: DEVICE
Intervention: Exercise with HFNC
Description: With constant flows of 50 lpm and with FiO2 adjusted according to SPO2, to obtain a constant saturation between 92 and 94%. The same pedaling load and frequency will be maintained, with similar variables collected.
Study NCT03231527 — intervention group
Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting (CABG)
Description: myocardial revascularization
Study NCT03568500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Medicine System
Description: DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).
Study NCT04654416 — intervention group
Intervention type: DRUG
Intervention: Corticosteroid with or without colchicine
Description: We describe the clinical outcome of patients treated with corticosteroid and colchicine
Study NCT04241861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory support (High-flow oxygen therapy)
Description: Noninvasive respiratory support respiratory support
Study NCT04241861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory support (Helmet PSV)
Description: Noninvasive respiratory support respiratory support
Study NCT04241861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory support (Helmet CPAP)
Description: Noninvasive respiratory support respiratory support
Study NCT01535716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hemodynamic optimization strategy driven by the ECOM
Description: goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) \& cardiac index (CI).~goals:~* SVV \< 11%~* IC > 2,2 ml/min/m²~During the anesthesia
Study NCT01535716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard management strategy
Description: goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~* Diuresis > 0,5ml/kg/h~* Blood pressure , PAM > 65 mmHg~* Pulse pressure variation~* CVP 8 to 12 cmH20~* Visual aspect of the heart~* Overload signs During the anesthesia
Study NCT04706468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Capsules taken orally
Study NCT03568500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Dosage determined by the healthcare professionals.
Study NCT03568500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Dosage determined by the healthcare professionals.
Study NCT03568500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Dosage determined by the healthcare professionals.
Study NCT02827851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarticular administration of autologous SVF
Study NCT05465278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 18 months treatment with alirocumab
Study NCT04636099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT angiography（CTA）
Description: The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
Study NCT05797220 — intervention group
Intervention type: DRUG
Intervention: Botulinum Toxin Type A Injection [Botox]
Study NCT03568500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Dosage determined by the healthcare professionals.
Study NCT04706468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TG-1000
Description: Capsules taken orally
Study NCT05710601 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Operative laparoscopies carried out according to the most recent national guidelines and following the good clinical practice of our operative unit.
Study NCT01060982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic ablation device
Description: One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
Study NCT04310670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: The patient will be treated according to Lacanian psychoanalytic ethics, which allows to adequately respond to the patient's request for healing but who at the same time does not ignore the progress of scientific research in the neurological field
Study NCT04310670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy treatment will be articulated through the use of techniques designed to qualify the functionality of the subject divided by symptom: weakness, dystonic attitudes of the limbs, walking disorders, tremor.
Study NCT04310670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Invasive Brain Stimulation (NIBS)
Description: Diversified transcranial electrical maneuver protocols with an on-line or off-line approach may be applied for therapeutic purposes. This will include: transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), random noise stimulation (tRNS).
Study NCT02887976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoluMatrix™ Abiraterone Acetate
Description: SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor
Study NCT02887976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
Study NCT01821235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurontin® (gabapentin) batch A
Description: Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times
Study NCT01821235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurontin® (gabapentin) batch B
Description: Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
Study NCT01821235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabasandoz® (gabapentin) batch A
Description: Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times
Study NCT01821235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabasandoz® (gabapentin) batch B
Description: Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
Study NCT05797220 — intervention group
Intervention type: DRUG
Intervention: Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel
Study NCT04156191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-151 cream 0.15%
Description: ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
Study NCT02768961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines
Study NCT04156191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-151 cream 0.05%
Description: ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
Study NCT01590433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
Study NCT02768961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ledipasvir
Description: Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines
Study NCT01840267 — intervention group
Intervention type: DEVICE
Intervention: ultrasonographic measurement of optic nerve sheath diameter
Description: A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
Study NCT01590433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
Study NCT01898507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low nicotine cigarettes
Description: 15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.
Study NCT02491008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and \<4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study NCT01590433 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary counseling
Description: All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.
Study NCT01537926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
Study NCT03607006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient specific PEEK sheets
Description: Computer aided sheet design
Study NCT03607006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone shell
Description: autogenous retromolar/chin bone graft
Study NCT02531022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: A daily financial incentive framed as a loss of $2 each day goal is not acheived
Study NCT02531022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily feedback
Description: Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
Study NCT04287361 — intervention group
Intervention type: OTHER
Intervention: Efficacy of intravenous clonazepam
Description: Efficacy of intravenous clonazepam
Study NCT02491008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study NCT02065531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Soft Tissue Release
Description: Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
Study NCT02065531 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with impulse technique.
Description: Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
Study NCT03077724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Fish oil supplementation
Study NCT03077724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Olive Oil capsules
Study NCT03204097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral prophylaxis followed by placement of placebo gel
Study NCT03204097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Oral prophylaxis followed by placement of Alendronate gel
Study NCT03204097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aloe Vera
Description: Oral prophylaxis followed by placement of Aloe Vera gel
Study NCT00182754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Description: Given subcutaneously
Study NCT01537926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill manufactured to minic NAC 600mg capsule
Study NCT05859919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The drug Rutan 0.1.
Description: Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 0.1 100mg. Excipients: potato starch, calcium stearate, lactulose.
Study NCT05859919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic treatment
Description: Basic treatment without the drug Rutan 0.1.
Study NCT03741192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPEAC System
Description: Surface Electromyography (sEMG) based seizure monitoring and alerting system
Study NCT03478566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 monitoring
Description: The aim is to assess the accuracy of ambulatory, at home, transcutaneous CO2 monitoring in pediatric Neuromuscular Disease (NMD).
Study NCT00182754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given subcutaneously
Study NCT01235468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ex vivo expansion
Description: ex-vivo expansion of cord blood for transplantation
Study NCT03877445 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: exposition half-face
Description: Patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control. The effect of blue light on the melasma lesions will be assessed from Day 1 to Day 6 using chromametry and a modified Melasma Area and Severity Index on standardized photographs
Study NCT04622774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGC936
Description: Antibody Drug Conjugate
Study NCT00612716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
Study NCT00612716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
Study NCT00612716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Infused on Day 0
Study NCT00612716 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 165 cGy morning and evening on days -4 through -1.